Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stereotactic radiotherapy + trastuzumab deruxtecan
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, External Radiation
01
Overview
SRT + T-DXd is a combination therapy that pairs stereotactic radiotherapy (SRT) with trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate. T-DXd consists of a humanized HER2-targeting antibody (trastuzumab) linked to a topoisomerase I inhibitor payload (deruxtecan). This combination approach is being investigated for treating HER2-positive breast cancer, particularly in cases with metastatic disease. The TENDANCE study has shown that concurrent administration of T-DXd and radiotherapy (including SRT) appears to be safe with manageable toxicity and promising efficacy outcomes.
- Brand names
- Enhertu
- Other names
- stereotactic radiotherapy combined with Trastuzumab-Deruxtecan
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on stereotactic radiotherapy + trastuzumab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stereotactic radiotherapy + trastuzumab deruxtecan.